Teneobio, Inc.
https://www.teneobio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Teneobio, Inc.
Amgen Rebuilt R&D Platform To Focus On Speed And Access
The company explained during its recent business review how its R&D organization is pursuing the strategic objectives of improving success rates, reducing cycle times and enabling access to novel drugs.
Amgen CEO Bradway On Deals: Good (Smaller) Opportunities Are Vast
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.
Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.
Pharma Outlook 2022: What Next After A Year Of Innovation And Growth?
The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Transgenics
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- OMT Therapeutics Inc
- Recombinant Antibody Technology (RAT) Ltd.